Jessica Merrill
Latest From Jessica Merrill
CDK4/6 Market: Is A Shakeup Underway?
Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.
Viatris Pipeline Progress Includes Eylea, Botox Biosimilars
In its first sales and earnings call, Viatris management updated investors on the development of some key complex generics and biosimilars.
Bayer's Finerenone Stacks Up More CV Benefit Data Ahead Of Potential Approval
The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.
Pfizer DMD Gene Therapy Phase III Trial Stalled In US After FDA Questions On Potency Assays
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.
S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line
Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.
Pfizer DMD Gene Therapy Phase III Trial Faces A US Delay; Can Sarepta Close The Gap?
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.